CytoVale is a technology company.
CytoVale has raised $184.1M across 3 funding rounds.
CytoVale has raised $184.1M in total across 3 funding rounds.
CytoVale has raised $184.1M in total across 3 funding rounds.
CytoVale's investors include Accomplice VC, Alumni Ventures, Aniq Kassam, Matrix, Night Capital, SignalFire, Susa Ventures, Elliott Cohen, Sunil Paul, Travis May, Entrée Capital Ventures, Insight Partners.
Cytovale is a commercial-stage medical diagnostics company headquartered in South San Francisco, California, specializing in rapid diagnostic technologies for immune-mediated diseases, with a primary focus on early sepsis detection.[1][2][3] Its flagship product, IntelliSep, is an FDA-cleared test that uses microfluidics, machine learning, and biomechanical analysis of white blood cells from a standard blood draw to stratify sepsis risk in 8-10 minutes, serving emergency departments (EDs) to enable faster triage, reduce unnecessary antibiotics and blood cultures, shorten hospital stays, and cut costs.[1][2][3][5] Sepsis, the leading cause of hospital deaths in the U.S. (claiming 270,000 lives annually), remains Cytovale's core target, addressing diagnostic challenges in this fast-moving, dysregulated immune response condition; the company reported $33M in revenue and earned Modern Healthcare's 2024 Best in Business recognition for IntelliSep's clinical and financial impact.[1][3]
Cytovale traces its roots to academic research starting in 2007, officially incorporating in 2013 to commercialize microfluidic deformability cytometry for innate immune response analysis.[1][4] Co-founder and CTO Henry Tse, PhD, a key inventor with expertise in microfluidics, cancer biology, image processing, and clinical studies (BS from UC San Diego, PhD from UCLA), drove the core technology, backed by peer-reviewed publications and patents.[4] Co-founder and CEO Ajay Shah leads the mission to transform sepsis care, emphasizing the condition's deadliness.[3] The idea emerged from unmet needs in rapid sepsis diagnosis; early traction built through FDA clearance for IntelliSep and partnerships with hospitals like St. Francis Medical Center, evolving into a venture-backed firm supported by Norwest Venture Partners, Sands Capital, and Global Health Investment Corporation.[3][4][6]
Cytovale rides the wave of AI-driven precision diagnostics in biotech, targeting immune-mediated diseases amid rising sepsis burdens—exacerbated by aging populations, antimicrobial resistance, and post-pandemic hospital strains.[1][2][3] Timing is critical: sepsis kills more than opioids, prostate/breast cancer combined, costing hospitals billions; IntelliSep fills a gap in early, objective detection at presentation, influencing ED workflows and sepsis protocols nationwide.[2][3][5] Market forces like value-based care, ED overcrowding, and demand for rapid, cost-saving tools favor expansion; as a B2B healthcare innovator, Cytovale shapes the ecosystem by partnering with health systems, publishing data-driven best practices, and paving the way for broader immune profiling applications.[1][3][6]
Cytovale's momentum—fueled by IntelliSep's validation, revenue growth, and awards—positions it for national scaling and pipeline expansion into other immune diseases like infections or autoimmunity.[1][3] Trends in AI-biotech convergence, regulatory tailwinds for rapid tests, and hospital focus on sepsis bundles will accelerate adoption, potentially amplifying influence through health system networks and new indications.[1][3][5] Watch for deepened integrations, clinical outcome publications, and funding rounds to fuel growth; as sepsis detection evolves from reactive to proactive, Cytovale stands to redefine ED standards, saving lives and echoing its founding promise of immune insight at speed.[3][4][6]
CytoVale has raised $184.1M across 3 funding rounds. Most recently, it raised $100.0M Series D in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2024 | $100.0M Series D | Accomplice VC, Alumni Ventures, Aniq Kassam, Matrix, Night Capital, SignalFire, Susa Ventures, Elliott Cohen, Sunil Paul, Travis May | |
| Nov 1, 2023 | $84.0M Series C | Alumni Ventures, Entrée Capital Ventures, Insight Partners, Mercury Fund, Norwest Venture Partners, Pitango Venture Capital | |
| May 1, 2018 | $65K Series B | Ankona Capital, Ehukai Investments |